Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Focused on satiety and appetite signals Interesting as a supplement within broader metabolic research High purity and consistent laboratory quality Much studied in combination with GLP-1-related peptides Important For research purposes only
The babies in the research study developed normally with no reported problems
In the trial studied for tirzepatide (SURMOUNT-1), participants lost about 20.9% of body weight at the top dose, and in the trial studied for semaglutide (STEP 1), participants lost about 14.9%
Common contraindications cited in the research-use community include: anyone with active or recent cancer (BPC-157 and TB-500 promote angiogenesis), people with Wilson's disease or other copper-metabolism disorders (GHK-Cu component), anyone pregnant or breastfeeding (no safety data), and athletes subject to WADA testing (BPC-157 and TB-500 are prohibited)
Vascular recruitment the organised attraction of new blood vessel ingrowth into healing tissue is considered a central mechanism across BPC-157s cross-tissue cytoprotective effects and is described as a defining feature distinguishing it from other growth factors in the healing biology literature
Technology such as radiofrequency skin tightening, laser lipo, ultrasound sculpting, EMS muscle toning, and lymphatic contouring are effective options
